Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.
Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M Greer, Richard Piekarz, Judith E Karp, Keith W Pratz, Michelle A Rudek
Open access · bronzeAbstract readClinical Trial, Phase II
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 1 institution in 1 country.
Shailly MehrotraCenter for Translational Medicine, University of Maryland, Baltimore, Maryland.
Mathangi GopalakrishnanCenter for Translational Medicine, University of Maryland, Baltimore, Maryland. mrudek2@jhmi.edu mgopalakrishnan@rx.umaryland.edu.
Jogarao GobburuCenter for Translational Medicine, University of Maryland, Baltimore, Maryland.
Jiuping JiFrederick National Laboratory for Cancer Research, Frederick, Maryland.
Jacqueline M GreerThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Richard PiekarzInvestigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Judith E KarpThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Keith W PratzThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Michelle A RudekThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. mrudek2@jhmi.edu mgopalakrishnan@rx.umaryland.edu.
Johns Hopkins University · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
The Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9M
PHASE I TRIALS OF ANTICANCER AGENTSU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARDUCCI, MICHAEL A · 1995 to 2013
$8.6M
Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI JABBOUR, SALMA, LIU, GLENN · 2014 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. · full record | OpenQuestion